Triple GIP/GLP-1/glucagon receptor co-agonists The success of dual receptor agonists for the treatment of type 2 diabetes and obesity in clinical trials, including the approval of one such drug by the FDA and EMA (currently only for type 2 diabetes), has prompted the search for new combinatorial approaches
First, several molecules appear under multiple brand names at different doses for different indications, which is why patients are frequently confused about whether Ozempic and Wegovy are "the same drug." They contain the same active molecule at different maximum doses with different approved uses
The high cost of brand-name drugs is due to R&D, marketing, and patent protection
For back pain related to poor circulation or injury, improved blood flow can aid in the recovery process
Temperature-controlled shipping thermal packaging with ice gel / cold packs preserves stability
Blood sugar spikes were more common after meals, and my weight crept back up